JAMA Network
About The Study: Although phase 3 trials are often interpreted as demonstrating superiority, overall survival and quality of life (QOL), which may be the most relevant end points to patients, are uncommonly improved. To increase the meaningfulness of late-phase research, future trial designs and regulatory processes should be refocused toward overall survival and QOL improvements.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
